Clinical Trial: The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: The Effect of an Oral Antioxidant, N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis
Brief Summary: This is a pilot study investigating the effect of an antioxidant, N-Acetyl-L-Cysteine (NAC), on inflammation and oxidative stress in sarcoidosis.
Detailed Summary: Sarcoidosis is a granulomatous lung disease predominantly affecting the lungs. Reactive oxidative species are produced secondary to oxidative stress and inflammation and can affect key cellular processes. The investigators have shown a role for oxidative stress in chronic beryllium disease (CBD), a granulomatous disease that resembles sarcoidosis, and have also shown that antioxidant therapy reduces inflammation in CBD. Oxidative stress also plays a role in sarcoidosis but the exact mechanism and potential effect of antioxidant therapy on sarcoidosis is unknown. The investigators propose conducting a pilot study investigating the effect of an antioxidant, N-Acetyl-L-Cysteine (NAC), on inflammation and oxidative stress in sarcoidosis. The investigators will measure and compare markers of inflammation and oxidative stress in the lungs of sarcoidosis patients before and after treatment with NAC. The results of this study will prepare the investigators for a larger study investigating the role of NAC as a therapy for sarcoidosis with changes in lung function and x-ray as our primary outcome. This will provide the investigators with a new non-toxic therapy for sarcoidosis that can be used on its own or to supplement other therapies minimizing their toxicity.
Sponsor: National Jewish Health
Current Primary Outcome: Bronchoalveolar Lavage (BAL) and Peripheral Blood Mononuclear Cells (PBMC) TNF-α Levels [ Time Frame: 8 weeks of anti-oxidant therapy ]
Original Primary Outcome: Effect of an oral anti-oxidant on lung inflammation [ Time Frame: change in lung inflammation after 8 weeks of anti-oxidant therapy ]
Current Secondary Outcome: Bronchoalveolar Lavage (BAL) Cell Glutathione (GSH) Levels [ Time Frame: 8 weeks of anti-oxidant therapy ]
Original Secondary Outcome: Effect of an oral anti-oxidant on lung oxidative stress [ Time Frame: change in lung oxidative stress after 8 weeks of anti-oxidant therapy ]
Information By: National Jewish Health
Dates:
Date Received: January 10, 2012
Date Started: November 2011
Date Completion:
Last Updated: March 27, 2017
Last Verified: March 2017